|
" Atherosclerosis, Hypertension and Diabetes "
edited by Grant N. Pierce, Makoto Nagano, Peter Zahradka, Naranjan S. Dhalla.
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
734286
|
| Doc. No
|
:
|
b554117
|
| Main Entry
|
:
|
edited by Grant N. Pierce, Makoto Nagano, Peter Zahradka, Naranjan S. Dhalla.
|
| Title & Author
|
:
|
Atherosclerosis, Hypertension and Diabetes\ edited by Grant N. Pierce, Makoto Nagano, Peter Zahradka, Naranjan S. Dhalla.
|
| Publication Statement
|
:
|
Boston, MA: Springer US, 2003
|
| Series Statement
|
:
|
Progress in experimental cardiology, 8.
|
| Page. NO
|
:
|
(xxi, 492 pages)
|
| ISBN
|
:
|
1441992324
|
|
|
:
|
: 9781441992321
|
| Contents
|
:
|
I. Atherosclerosis And Cardiovascular Disease --;1. PPAR-Alpha in Lipid and Lipoprotein Metabolism, Vascular Inflammation and Atherosclerosis --;2. The Choice of an Appropriate Animal Species in the Study of Chlamydia pneumoniae as an Atherogenic Agent --;3. Endothelial Cell Dysfunction --;A Key Factor in Atherogenesis and its Reversal (Laboratory and Clinical Study) --;4. Biochemical Mechanisms of Hyperhomocysteinemia in Atherosclerosis: Role of Chemokine Expression --;5. Oxyradicals and Hypercholesterolemic Atherosclerosis --;6. Identification, Regulation and Function of LOX-1, A Novel Receptor for Ox-LDL --;7. Atherosclerosis and Angiotensin II in Hypercholesterolemia and Diabetes. A Role for ATt Receptors Beyond Hypertension --;8. Basic and Clinical Results of New Statin: Pitavastatin --;9. Reducing Cardiovascular Risk With HMG CoA Reductase Inhibitors, Potential Contribution From Platelets --;10. Rapamycin-Sensitive Signal Transduction Pathways and the Control of Adipogenesis --;II. Hypertension --;11. Genetic Predisposition to Hypertension and Cardiovascular Disease --;12. Role of Sympathetic Nervous System in Hypertension --;13. Role of Hypothalamic Peptides in the Development of Hypertension --;14. Myosin Light Chain Kinase in Endothelial Cell Calcium Signaling and Endothelial Functions --;15. Sarpogrelate Inhibits Genes Involved in Vascular Neointimal Hyperplasia and Remodeling --;16. A Nutritional Approach to Prevent High Blood Pressure --;17. Cardiovascular and Renal Actions of Leptin --;18. Brain Na, K-ATPase Enzymatic Activity and Cardiovascular Regulation --;19. Development of Transdermal and Transbuccal Drug Delivery Systems for Cardioactive Drugs with Special Reference to Anti-Hypertensive Agents --;20. Insulin Resistance and Experimental Hypertension --;III. Diabetes Mellitus --;21. New Paradigm for Insulin Resistance: The HISS Story --;22. Vanadium Effects in Diabetes --;23. Dyslipoproteinemia and Fibrinolysis --;24. Endothelins and Cardiovascular Disease in Diabetes --;25. Usefulness of 5-HT2A Receptor Antagonists for the Treatment of Cardiovascular Complications in Diabetes --;26. Selective Attenuation of Enhanced Angiotensin II Mediated Responses in the Streptozotocin Diabetic Rat Thoracic Aorta by Tempol --;27. Role of Renin-Angiotensin System in Diabetic Heart Dysfunction and Changes in Phospholipase C Activity --;28. Regulation of Cardiac Function in Diabetes --;29. Diabetes and Cardiac Dysfunction --;30. Mechanisms Underlying Contractile Dysfunction in Streptozotocin-Induced Type 1 and Type 2 Diabetic Cardiomyopathy --;31. Protein Kinase C Signaling and Expression of the Diabetic Cardiac Phenotype --;32. Oxidative Stress in Cardiovascular Complications of Diabetes --;33. Augmented Energy Transfer in Rat Heart Mitochondria: Compensatory Response to Abnormal Household of Energy in Acute Diabetes --;34. Ketosis, Tumor Necrosis Factor-a and Cardiovascular Disease in Type-1 Diabetic Patients --;35. Epigenetic Alterations in Diabetic Cardiomyopathy.
|
| Abstract
|
:
|
This volume is devoted to atherosclerosis, hypertension, and diabetes, three of the most important disease conditions in the world today. Nutritional intervention, cholesterol lowering agents, lipids themselves, particularly oxidized LDL, protein modification by ADP-ribose, bone marrow study, endothelial cell dysfunction, angiotensin, and the role of infection and inflammation are all discussed in the context of atherosclerotic cardiovascular disease. The hypertension section focuses on factors that may be responsible for high blood pressure, such as genetic predisposition, vascular hyperplasia and remodeling, insulin resistance, neurological aspects such as hypothalamic peptides. Also discussed are the possible contributions of the cellular function of the endothelium, nutrition, kidney dysfunction, leptin, and the brain. Novel routes of drug delivery for treatment of hypertension is also a focus. The risk factors and mechanisms responsible for diabetic vascular and cardiac dysfunction are discussed. Lipid profile changes and fibrinolysis in diabetic patients is detailed, along with adipogenesis, diabetic cardiomyopathy, energy metabolism in the diabetic heart, vanadate as an alternative to insulin, insulin resistance mechanisms, and neurotransmitters as targets for the prevention of cardiovascular disease and diabetes.
|
| Subject
|
:
|
Cardiology.
|
| Subject
|
:
|
Medicine.
|
| LC Classification
|
:
|
RC692.E358 2003
|
| Added Entry
|
:
|
Grant N Pierce
|
|
|
:
|
Makoto Nagano
|
|
|
:
|
Naranjan S Dhalla
|
|
|
:
|
Peter Zahradka
|
| |